Cardiovascular Diseases

818 trials 341 recruiting

Filter these 818 trials by phase, country and sponsor.

Open in Search →

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants with Multiple System Atrophy Ended

2023-504876-12-00 Neurogenic Orthostatic Hypotension 5 2023-10-25
Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery disease Ended

2023-507015-35-00 Coronary Artery Disease 5 2023-10-06
A single arm, open label extension (OLE), multicenter study to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in patients… Ended

2023-503611-16-00 Apheresis 5 2023-09-29
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes (REC1TE): a randomized, double-blind, placebo-controll… Ended

2022-502038-23-00 Type 1 diabetes 4 2023-08-25
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
HAnnover ChOlesterol Lowering study in ACS Ended

2024-513703-13-00 Coronary artery disease/myocardial infarction 5 2023-06-30
Semmelweis Lipid Center for High-risk Patients Ended

2024-519058-35-00 primary hypercholesterolaemia (heterozygous familial an 6 2023-05-30
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
TEMP-PREVENT Ended

2024-512133-33-00 Pseudoxanthoma Elasticum 5 2023-04-26
Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device-related intra-cardia… Ended

2024-512685-33-00 intra-cardiac thrombus 5 2023-04-11
DANNOAC- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study Ended

2022-501912-32-00 Atrial Fibrillation (and atrial flutter), deep vein tro 6 2023-04-01
Bicarbonate for the treatment of cardiac arrest Ended

2022-501304-10-00 In-hospital cardiac arrest 6 2023-02-06
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P… Ended

2024-511126-31-00 Non-obstructive Coronary Artery Disease 5 2022-08-16
Does the use of empagliflozin improve exercise capacity in patients with hypertrophic cardiomyopathy. Ended

2024-517643-31-00 Hypertrophic cardiomyopathy 5 2022-06-22
Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial Ended

2024-515226-81-00 Myocardial Injury after Noncardiac Surgery 5 2022-06-02
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
LEGACY Ended

2023-504360-42-00 Non-ST-segment elevation acute coronary syndrome 6 2022-05-13
DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients Ended

2023-506486-60-01 Heart transplant 5 2022-04-26
Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial arrhythmia or Tachycardia Ended

2024-513324-42-00 Patent Foramen Ovale Closure Atrial Arrhytmia or Tachy 5 2022-03-23
An Open-Label Extension and Safety Monitoring Study of Acoramidis(AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopath… Ended

2024-515092-36-00 Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR- 5 2022-02-14
Blood thinners after transcatheter implantation of a new heart valve in patients with aortic stenosis Ended

2023-510211-20-00 Aortic stenosis 5 2021-12-07